Vasoactive therapy versus placebo in the treatment of sudden hearing loss: A double‐blind clinical study

Jona Kronenberg; Moshe Almagor; Erez Bendet; Dana Kushnir

doi:10.1288/00005537-199201000-00013

Vasoactive therapy versus placebo in the treatment of sudden hearing loss: A double‐blind clinical study

Jona Kronenberg, Moshe Almagor, Erez Bendet, Dana Kushnir

Department of Psychology

Research output: Contribution to journal › Article › peer-review

Abstract

Twenty‐seven patients suffering from sudden sensorineural hearing loss (SHL) were randomly assigned to one of two groups: a treatment group (n = 13) receiving intravenous procaine and low‐molecular‐weight dextran, and a placebo control group (n = 14). The effect of treatment was analyzed by means of an analysis of variance and covariance procedures. Results indicated nonsignificant differences between the groups on all outcome indices measured. Sex, age, time since the onset of symptoms to the initiation of therapy, audiogram configuration, and initial severity of hearing loss did not significantly affect the results. These findings suggest that the therapeutic effects of this vasodilator are not superior to a placebo.

Original language	English
Pages (from-to)	65-68
Number of pages	4
Journal	Laryngoscope
Volume	102
Issue number	1
DOIs	https://doi.org/10.1288/00005537-199201000-00013
State	Published - Jan 1992

ASJC Scopus subject areas

Otorhinolaryngology

Access to Document

10.1288/00005537-199201000-00013

Cite this

@article{fe66e9ab4673425f9fac4d751bd9d939,

title = "Vasoactive therapy versus placebo in the treatment of sudden hearing loss: A double‐blind clinical study",

abstract = "Twenty‐seven patients suffering from sudden sensorineural hearing loss (SHL) were randomly assigned to one of two groups: a treatment group (n = 13) receiving intravenous procaine and low‐molecular‐weight dextran, and a placebo control group (n = 14). The effect of treatment was analyzed by means of an analysis of variance and covariance procedures. Results indicated nonsignificant differences between the groups on all outcome indices measured. Sex, age, time since the onset of symptoms to the initiation of therapy, audiogram configuration, and initial severity of hearing loss did not significantly affect the results. These findings suggest that the therapeutic effects of this vasodilator are not superior to a placebo.",

author = "Jona Kronenberg and Moshe Almagor and Erez Bendet and Dana Kushnir",

year = "1992",

month = jan,

doi = "10.1288/00005537-199201000-00013",

language = "English",

volume = "102",

pages = "65--68",

journal = "Laryngoscope",

issn = "0023-852X",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - Vasoactive therapy versus placebo in the treatment of sudden hearing loss

T2 - A double‐blind clinical study

AU - Kronenberg, Jona

AU - Almagor, Moshe

AU - Bendet, Erez

AU - Kushnir, Dana

PY - 1992/1

Y1 - 1992/1

N2 - Twenty‐seven patients suffering from sudden sensorineural hearing loss (SHL) were randomly assigned to one of two groups: a treatment group (n = 13) receiving intravenous procaine and low‐molecular‐weight dextran, and a placebo control group (n = 14). The effect of treatment was analyzed by means of an analysis of variance and covariance procedures. Results indicated nonsignificant differences between the groups on all outcome indices measured. Sex, age, time since the onset of symptoms to the initiation of therapy, audiogram configuration, and initial severity of hearing loss did not significantly affect the results. These findings suggest that the therapeutic effects of this vasodilator are not superior to a placebo.

AB - Twenty‐seven patients suffering from sudden sensorineural hearing loss (SHL) were randomly assigned to one of two groups: a treatment group (n = 13) receiving intravenous procaine and low‐molecular‐weight dextran, and a placebo control group (n = 14). The effect of treatment was analyzed by means of an analysis of variance and covariance procedures. Results indicated nonsignificant differences between the groups on all outcome indices measured. Sex, age, time since the onset of symptoms to the initiation of therapy, audiogram configuration, and initial severity of hearing loss did not significantly affect the results. These findings suggest that the therapeutic effects of this vasodilator are not superior to a placebo.

UR - http://www.scopus.com/inward/record.url?scp=0026601723&partnerID=8YFLogxK

U2 - 10.1288/00005537-199201000-00013

DO - 10.1288/00005537-199201000-00013

M3 - Article

C2 - 1370568

AN - SCOPUS:0026601723

SN - 0023-852X

VL - 102

SP - 65

EP - 68

JO - Laryngoscope

JF - Laryngoscope

IS - 1

ER -

Vasoactive therapy versus placebo in the treatment of sudden hearing loss: A double‐blind clinical study

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this